Results 61 to 70 of about 673 (120)

Xp11.2 Translocation Renal Cell Carcinoma: A Rare Renal Cell Carcinoma. [PDF]

Cureus, 2023
Kalita P, Dey B, Saurabh A, Chishti SF.
europepmc   +1 more source

The Transition From Localized to Metastatic: A Case Report of Adult TFE3-Positive Xp11.2 Translocation Renal Cell Carcinoma. [PDF]

Cureus, 2023
Naviwala MS, Dawood T, Uddin Z, Chundriger Q, Jalbani IK.   +4 more
europepmc   +1 more source

Targeting chemoresistance in Xp11.2 translocation renal cell carcinoma using a novel polyamide-chlorambucil conjugate. [PDF]

Cancer Sci, 2022
Funasaki S, Mehanna S, Ma W, Nishizawa H, Kamikubo Y, Sugiyama H, Ikeda S, Motoshima T, Hasumi H, Linehan WM, Schmidt LS, Ricketts C, Suda T, Oike Y, Kamba T, Baba M.   +15 more
europepmc   +1 more source

TFE3 fusions escape from controlling of mTOR signaling pathway and accumulate in the nucleus promoting genes expression in Xp11.2 translocation renal cell carcinomas

Journal of Experimental & Clinical Cancer Research, 2019
Background Xp11.2 translocation renal cell carcinoma (tRCC) is mainly caused by translocation of the TFE3 gene located on chromosome Xp11.2 and is characterized by overexpression of the TFE3 fusion gene. Patients are diagnosed with tRCC usually before 45 
Xiaoqin Yin, Bo Wang, Weidong Gan, Wenyuan Zhuang, Zou Xiang, Xiaodong Han, Dongmei Li   +6 more
doaj   +1 more source

Adult Xp11.2 translocation renal cell carcinoma managed effectively with pazopanib. [PDF]

BMJ Case Rep, 2021
Solano C, Thapa S, Chisti MM.
europepmc   +1 more source

Xp11.2 Translocation Renal Cell Carcinoma: Clinical Characteristics and Potential Prognostic Predictors. [PDF]

Dis Markers, 2021
Dong J, Xu W, Ji Z, Pan B.
europepmc   +1 more source

Case Report: TFE3 Positive Xp11.2 Translocation Renal Cell Carcinoma (TRCC) - A Case Study and Review of the Literature. [PDF]

Front Oncol, 2021
Miroński I, Zaucha JM, Kowalski J, Zaucha R.   +3 more
europepmc   +1 more source

A case of metastatic Xp11.2 translocation renal cell carcinoma showing a prolonged response to nivolumab as 6th-line treatment. [PDF]

Int Cancer Conf J, 2022
Yoshida T, Tanaka T, Shindo T, Kyoda Y, Hashimoto K, Kobayashi K, Hasegawa T, Masumori N.   +7 more
europepmc   +1 more source

Contrast-Enhanced Ultrasound Features of Adult Xp11.2 Translocation Renal Cell Carcinoma: Differential Diagnosis With Three Main Renal Cell Carcinoma Subtypes. [PDF]

J Ultrasound Med, 2022
Ma W, Zhang F, Huang H, Wang W, Zhu Y, Lu Y, Guo H, Gan W.   +7 more
europepmc   +1 more source

Abstracts

Cancer Science, Volume 115, Issue S1, Page 1-2243, March 2024.
wiley   +1 more source